Literature DB >> 31180336

SIRT1 regulates metabolism and leukemogenic potential in CML stem cells.

Ajay Abraham1, Shaowei Qiu1,2, Balu K Chacko3, Hui Li1, Andrew Paterson1, Jianbo He1, Puneet Agarwal1, Mansi Shah1, Robert Welner1, Victor M Darley-Usmar3, Ravi Bhatia1.   

Abstract

Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the BCR-ABL kinase. Despite the success of BCR-ABL tyrosine kinase inhibitors (TKIs) in treating CML patients, leukemia stem cells (LSCs) resist elimination and persist as a major barrier to cure. Previous studies suggest that overexpression of the sirtuin 1 (SIRT1) deacetylase may contribute to LSC maintenance in CML. Here, by genetically deleting SIRT1 in transgenic CML mice, we definitively demonstrated an important role for SIRT1 in leukemia development. We identified a previously unrecognized role for SIRT1 in mediating increased mitochondrial oxidative phosphorylation in CML LSCs. We showed that mitochondrial alterations were kinase independent and that TKI treatment enhanced inhibition of CML hematopoiesis in SIRT1-deleted mice. We further showed that the SIRT1 substrate PGC-1α contributed to increased oxidative phosphorylation and TKI resistance in CML LSCs. These results reveal an important role for SIRT1 and downstream signaling mechanisms in altered mitochondrial respiration in CML LSCs.

Entities:  

Keywords:  Adult stem cells; Hematology; Leukemias; Oncology

Mesh:

Substances:

Year:  2019        PMID: 31180336      PMCID: PMC6597223          DOI: 10.1172/JCI127080

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

Authors:  Su Chu; Tinisha McDonald; Allen Lin; Sujata Chakraborty; Qin Huang; David S Snyder; Ravi Bhatia
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

2.  Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.

Authors:  Marie Lagouge; Carmen Argmann; Zachary Gerhart-Hines; Hamid Meziane; Carles Lerin; Frederic Daussin; Nadia Messadeq; Jill Milne; Philip Lambert; Peter Elliott; Bernard Geny; Markku Laakso; Pere Puigserver; Johan Auwerx
Journal:  Cell       Date:  2006-11-16       Impact factor: 41.582

3.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

4.  hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Authors:  H Vaziri; S K Dessain; E Ng Eaton; S I Imai; R A Frye; T K Pandita; L Guarente; R A Weinberg
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

5.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Authors:  Steffen Koschmieder; Berthold Göttgens; Pu Zhang; Junko Iwasaki-Arai; Koichi Akashi; Jeffery L Kutok; Tajhal Dayaram; Kristin Geary; Anthony R Green; Daniel G Tenen; Claudia S Huettner
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

6.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.

Authors:  Hwei-Ling Cheng; Raul Mostoslavsky; Shin'ichi Saito; John P Manis; Yansong Gu; Parin Patel; Roderick Bronson; Ettore Appella; Frederick W Alt; Katrin F Chua
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 7.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

8.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Authors:  Ashley Hamilton; G Vignir Helgason; Mirle Schemionek; Bin Zhang; Svetlana Myssina; Elaine K Allan; Franck E Nicolini; Carsten Müller-Tidow; Ravi Bhatia; Valerie G Brunton; Steffen Koschmieder; Tessa L Holyoake
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

9.  Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.

Authors:  Marcus J G W Ladds; Andrés Pastor-Fernández; Gergana Popova; Ingeborg M M van Leeuwen; Kai Er Eng; Catherine J Drummond; Lars Johansson; Richard Svensson; Nicholas J Westwood; Anna R McCarthy; Fredrik Tholander; Mihaela Popa; David P Lane; Emmet McCormack; Gerald M McInerney; Ravi Bhatia; Sonia Laín
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

10.  SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.

Authors:  Ling Li; Tereza Osdal; Yinwei Ho; Sookhee Chun; Tinisha McDonald; Puneet Agarwal; Allen Lin; Su Chu; Jing Qi; Liang Li; Yao-Te Hsieh; Cedric Dos Santos; Hongfeng Yuan; Trung-Quang Ha; Mihaela Popa; Randi Hovland; Øystein Bruserud; Bjørn Tore Gjertsen; Ya-Huei Kuo; Wenyong Chen; Sonia Lain; Emmet McCormack; Ravi Bhatia
Journal:  Cell Stem Cell       Date:  2014-10-02       Impact factor: 24.633

View more
  25 in total

Review 1.  A chromatin perspective on metabolic and genotoxic impacts on hematopoietic stem and progenitor cells.

Authors:  Zhenhua Yang; Hao Jiang
Journal:  Cell Mol Life Sci       Date:  2020-04-21       Impact factor: 9.261

Review 2.  New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism.

Authors:  Kazuhito Naka
Journal:  Int J Hematol       Date:  2021-03-05       Impact factor: 2.490

3.  Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition.

Authors:  Shaowei Qiu; Harish Kumar; Chengcheng Yan; Hui Li; Andrew J Paterson; Nicholas R Anderson; Jianbo He; Jing Yang; Min Xie; David K Crossman; Rui Lu; Robert S Welner; Ravi Bhatia
Journal:  Leukemia       Date:  2022-10-11       Impact factor: 12.883

Review 4.  Deciphering Metabolic Adaptability of Leukemic Stem Cells.

Authors:  Sweta B Patel; Travis Nemkov; Angelo D'Alessandro; Robert S Welner
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 5.  Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.

Authors:  John Joson Ng; S Tiong Ong
Journal:  Curr Hematol Malig Rep       Date:  2022-10-19       Impact factor: 4.213

Review 6.  Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors.

Authors:  Courtney L Jones; Anagha Inguva; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2021-03-04       Impact factor: 24.633

Review 7.  CD38: T Cell Immuno-Metabolic Modulator.

Authors:  Anwesha Kar; Shikhar Mehrotra; Shilpak Chatterjee
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

8.  Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma.

Authors:  Jiangtao Sun; Guifang Li; Yiwen Liu; Mingyang Ma; Kaifang Song; Huaxu Li; Daxing Zhu; XiaoJun Tang; Jinyu Kong; Xiang Yuan
Journal:  Neoplasia       Date:  2019-11-22       Impact factor: 5.715

Review 9.  Trending topics of SIRT1 in tumorigenicity.

Authors:  Liz M Garcia-Peterson; Xiaoling Li
Journal:  Biochim Biophys Acta Gen Subj       Date:  2021-06-18       Impact factor: 4.117

10.  PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions.

Authors:  Rama Krishna Nimmakayala; Sanchita Rauth; Ramakanth Chirravuri Venkata; Saravanakumar Marimuthu; Palanisamy Nallasamy; Raghupathy Vengoji; Subodh M Lele; Satyanarayana Rachagani; Kavita Mallya; Mokenge P Malafa; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.